Dr. Reddy’s Laboratories launches novel molecule ‘Tegoprazan’ in India

16 Sep 2025 Evaluate

Dr. Reddy’s Laboratories has launched the novel molecule ‘Tegoprazan’, for acid-related gastrointestinal diseases in India. The company launches Tegoprazan (50 mg) under the brand name PCAB. Tegoprazan is a next-generation potassium-competitive acid blocker. It is indicated for the treatment of acid peptic diseases (APD) such as Erosive Gastroesophageal Reflux Disease (GERD), Non-Erosive Gastroesophageal Reflux Disease (NERD) and Gastric Ulcer. Tegoprazan induces fast onset of action and can control gastric pH for a prolonged period, potentially offering significant clinical benefit in APD management.

Recent data indicates that APD affects around 38% of the Indian population, highlighting its widespread prevalence and the growing need for effective management strategies. The launch of Tegoprazan by the company aims to bridge the gap in the treatment option for acid peptic diseases. In a multinational clinical trial conducted by the company across India, South Africa and Russia, 99% of GERD patients in the Tegoprazan treatment arm achieved endoscopic healing by Week 8. Tegoprazan is already approved in 21 countries, including South Korea and China. It is currently under registration in several countries and has successfully completed Phase-III trial in the United States.

Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.

Dr. Reddys Lab Share Price

1175.55 -10.90 (-0.92%)
16-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1669.20
Dr. Reddys Lab 1175.55
Cipla 1397.95
Zydus Lifesciences 867.80
Lupin 2176.25
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×